- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Fluorescence activated cell sorting.
Displaying page 1 of 1.
EudraCT Number: 2019-000836-24 | Sponsor Protocol Number: IIV-406 | Start Date*: 2019-06-19 |
Sponsor Name:National Institute of Health and the Environment | ||
Full Title: Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults. | ||
Medical condition: Healthy volunteers above 25 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000911-26 | Sponsor Protocol Number: Uni-Koeln-1392 | Start Date*: 2011-05-12 |
Sponsor Name:University of Cologne | ||
Full Title: Heart rate control after acute myocardial infarct | ||
Medical condition: successful percutaneous intervention in patients with acute ST-elevated myocardial infarct | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003056-36 | Sponsor Protocol Number: CBAF312A2304 | Start Date*: 2012-10-31 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro... | |||||||||||||
Medical condition: Secondary progressive multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) IE (Completed) DE (Prematurely Ended) CZ (Completed) SK (Completed) NL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) SE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) LV (Completed) GR (Completed) LT (Completed) EE (Completed) BE (Prematurely Ended) PL (Completed) BG (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002106-13 | Sponsor Protocol Number: ATH3G10-005 | Start Date*: 2017-09-06 | |||||||||||
Sponsor Name:Athera Biotechnologies AB | |||||||||||||
Full Title: Double-blind, randomised, placebo-controlled, multicentre, Phase IIa study to investigate the effect of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together ... | |||||||||||||
Medical condition: Arterial inflammation in subjects with elevated lipoprotein a (Lp[a]) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005341-38 | Sponsor Protocol Number: P04720 | Start Date*: 2008-06-09 |
Sponsor Name:Schering Plough Research Institute | ||
Full Title: A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing’s Sarcoma That Has Relapsed After Standard Systemic Therapy. | ||
Medical condition: Relapsed resectable and unresectable Osteosarcoma, Ewing Sarcoma. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) ES (Completed) SE (Prematurely Ended) NO (Prematurely Ended) NL (Completed) IT (Completed) CZ (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001737-85 | Sponsor Protocol Number: 80-84800-98-81014 | Start Date*: 2018-07-17 | |||||||||||
Sponsor Name:academic medical centre | |||||||||||||
Full Title: Efficacy of AlbenDazole to inDuce mUcosal healing in Patients with Crohn's disease on anti-TNF monotherapy | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003652-32 | Sponsor Protocol Number: ISA101b-OPC-03-19 | Start Date*: 2021-04-13 | |||||||||||
Sponsor Name:ISA Therapeutics B.V. | |||||||||||||
Full Title: A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16- positive Oropharyngeal Cancer who have experienced disease progres... | |||||||||||||
Medical condition: Recurrent/metastatic HPV16- positive Oropharyngeal Cancer (OPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004303-19 | Sponsor Protocol Number: BSX - 001 | Start Date*: 2007-04-25 | |||||||||||
Sponsor Name:Cerimon Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulc... | |||||||||||||
Medical condition: Steroid-refractory ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) CZ (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001238-16 | Sponsor Protocol Number: CNTO1959PSO3012 | Start Date*: 2019-01-03 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Type Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000225-30 | Sponsor Protocol Number: DMA-Clin-199-2013-001 | Start Date*: 2013-04-12 | |||||||||||
Sponsor Name:DiaMedica USA Inc. | |||||||||||||
Full Title: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS... | |||||||||||||
Medical condition: Diabetes Mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
